Add to ORKG186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0·004), better overall response (p = 0·0001), and longer overall survival and progression-free survival (p<0·002). Therapy, histological grade, and Karnofsky index were reliable predictors of overall response, whereas therapy, FIGO-stage, and size of residual tumour before chemotherapy were independent predictors for complete remission and for ...
The purpose of this systematic study was to provide an up to date and reliable quantitative summary ...
The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in ...
Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent ...
186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of he...
In two studies initiated in 1979 and 1981, 377 patients were treated for advanced epithelial ovarian...
After primary surgery, 125 patients with epithelial ovarian cancer (International Federation of Gyna...
A combination chemotherapy including cisplatin, 25 mg/m2 on Days 1,8; methotrexate, 30 mg/m2 on Day ...
Summary. The concept of using either alternating or sequential combination chemotherapy with non-cro...
One hundred and twenty-five patients with advanced epithelial ovarian cancer (EOC) were postsurgical...
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to re...
The North West Oncology Group is a cooperative group that has carried out several clinical trials on...
PURPOSE: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after ...
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...
The purpose of this systematic study was to provide an up to date and reliable quantitative summary ...
Primary chemotherapy for ovarian cancer has evolved over the past 30 years from the use of single al...
The purpose of this systematic study was to provide an up to date and reliable quantitative summary ...
The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in ...
Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent ...
186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of he...
In two studies initiated in 1979 and 1981, 377 patients were treated for advanced epithelial ovarian...
After primary surgery, 125 patients with epithelial ovarian cancer (International Federation of Gyna...
A combination chemotherapy including cisplatin, 25 mg/m2 on Days 1,8; methotrexate, 30 mg/m2 on Day ...
Summary. The concept of using either alternating or sequential combination chemotherapy with non-cro...
One hundred and twenty-five patients with advanced epithelial ovarian cancer (EOC) were postsurgical...
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to re...
The North West Oncology Group is a cooperative group that has carried out several clinical trials on...
PURPOSE: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after ...
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...
The purpose of this systematic study was to provide an up to date and reliable quantitative summary ...
Primary chemotherapy for ovarian cancer has evolved over the past 30 years from the use of single al...
The purpose of this systematic study was to provide an up to date and reliable quantitative summary ...
The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in ...
Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent ...